- Home
- NUVB vs BHRB Comparison
NUVB vs BHRB Comparison
Compare NUVB & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BHRB
- Stock Information
- Founded
- NUVB 2018
- BHRB 1852
- Country
- NUVB United States
- BHRB United States
- Employees
- NUVB N/A
- BHRB N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BHRB Major Banks
- Sector
- NUVB Health Care
- BHRB Finance
- Exchange
- NUVB Nasdaq
- BHRB Nasdaq
- Market Cap
- NUVB 837.0M
- BHRB 852.6M
- IPO Year
- NUVB N/A
- BHRB N/A
- Fundamental
- Price
- NUVB $3.89
- BHRB $62.90
- Analyst Decision
- NUVB Strong Buy
- BHRB Strong Buy
- Analyst Count
- NUVB 6
- BHRB 3
- Target Price
- NUVB $8.00
- BHRB $71.67
- AVG Volume (30 Days)
- NUVB 6.2M
- BHRB 47.0K
- Earning Date
- NUVB 11-05-2025
- BHRB 10-24-2025
- Dividend Yield
- NUVB N/A
- BHRB 3.50%
- EPS Growth
- NUVB N/A
- BHRB N/A
- EPS
- NUVB N/A
- BHRB 6.89
- Revenue
- NUVB $14,355,000.00
- BHRB $330,001,000.00
- Revenue This Year
- NUVB $332.80
- BHRB $51.44
- Revenue Next Year
- NUVB $360.12
- BHRB $3.58
- P/E Ratio
- NUVB N/A
- BHRB $9.13
- Revenue Growth
- NUVB 900.35
- BHRB 164.69
- 52 Week Low
- NUVB $1.54
- BHRB $47.57
- 52 Week High
- NUVB $4.09
- BHRB $75.32
- Technical
- Relative Strength Index (RSI)
- NUVB 83.37
- BHRB 56.20
- Support Level
- NUVB $2.87
- BHRB $62.44
- Resistance Level
- NUVB $3.08
- BHRB $64.24
- Average True Range (ATR)
- NUVB 0.22
- BHRB 1.40
- MACD
- NUVB 0.08
- BHRB 0.21
- Stochastic Oscillator
- NUVB 86.52
- BHRB 76.02
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.